In liver fibrosis, the cannabinoid receptors CB1 and CB2 exhibit opposite roles: CB1 activation accentuates hepatic fibrosis progression whereas CB2 displays anti-fibrogenic and anti-inflammatory activities. This evidence concerns the gene CNR2 and Hepatic fibrosis.